Genomic Confidence

Some oncologists are rather gung-ho about using multiplex genomic tests and ready to use them to evaluate tumors and develop treatments for most of their patients, but others are much more wary about these gadgets, a new study finds.

The survey results, published in the Journal of Clinical Oncology, suggests there is "wide variation" in attitudes among cancer doctors about using multiplex tests to hunt for hundreds of variations in tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Just Another Test

Very Own Mouse

In This Case…

This Week in Science

The Pair of Them

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.